| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Mouse |
| Target | TAG-72 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| (verify) | |
Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer,[1] which acts as a tumor-targeted superantigen.[2]
It is a fusion protein of a human tumor-associated 5T4 antigen monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.[3]
Development was abandoned in 2005.[4]
References
- ^ "Active Biotech". activebiotech.com. Retrieved 25 May 2016.
- ^ Hedlund G, Forsberg G, Nederman T, Sundstedt A, Dahlberg L, Tiensuu M, Nilsson M (2013). "Tumor-Targeted Superantigens". Fusion Protein Technologies for Biopharmaceuticals. pp. 365–381. doi:10.1002/9781118354599.ch24. ISBN 9781118354599.
- ^ "Drug info" (PDF). World Health Organization. Retrieved 25 May 2016.
- ^ "Anatumomab mafenatox". AdisInsight. Springer Nature Switzerland AG.